Blade (BLDE) Q2 Revenue Jumps 10%
Blade Air Mobility (NASDAQ:BLDE), a provider of air transportation services specializing in both medical organ transport and on-demand passenger flights, released its Q2 2025 results on August 5, 2025. The earnings release highlighted GAAP revenue of $70.8 million, exceeding analyst expectations of $64.1 million (GAAP) by more than $6.7 million, or 10.5%. Earnings per share (GAAP) matched consensus at $(0.04). The most notable development is the planned divestiture of the Passenger division to Joby Aviation, which will transform Blade into a specialized medical air mobility company. The quarter saw noticeable year-over-year profitability improvements, led by medical services growth. However, free cash flow (non-GAAP) turned negative and medical segment margins came under pressure due to higher maintenance costs. Overall, the quarter was defined by operational progress in Blade’s core medical business and a strategic pivot away from passenger-facing operations.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Blade Air Mobility operates two main lines of business: on-demand helicopter and jet passenger flights in urban markets, and MediMobility Organ Transport services for hospitals and transplant centers. The firm's most significant recent move is its decision to divest its Passenger segment. This decision means Blade will become a dedicated medical air mobility operator, soon rebranding as Strata, and will focus fully on critical healthcare logistics for organ transport and related services.
Source Fool.com
